Physician profile
Mourad Alsabbagh
NPI 1124240890
$69,271.24
in general payments reported to CMS, 2019-2025
17 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.30 · 2021: $22.04 · 2022: $278 · 2023: $20K · 2024: $37K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,812.50 |
| Food and Beverage | $1,067.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $67,812.50 | 2023-2025 | |
| Veloxis Pharmaceuticals, INC. | $377.39 | 2022-2024 | Envarsus |
| Bayer Healthcare Pharmaceuticals INC. | $211.41 | 2025 | |
| Vifor Pharma, INC. | $160.77 | 2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $136.40 | 2023 | Terlivaz |
| Amgen INC. | $122.15 | 2022-2025 | Krystexxa, Tavneos |
| Boston Scientific Corporation | $91.30 | 2019 | |
| Corcept Therapeutics | $75.20 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $67.20 | 2021-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $47.41 | 2024-2025 | Velphoro, Velphoro |
| Takeda Pharmaceuticals U.S.A., INC. | $44.75 | 2022 | |
| Calliditas Therapeutics US INC. | $41.76 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $18.42 | 2025 | Lupkynis |
| Ferring Pharmaceuticals INC. | $17.34 | 2023 | Clenpiq |
| Otsuka America Pharmaceutical, INC. | $17.06 | 2025 | Jynarque |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $15.53 | 2022 | |
| Ardelyx, INC. | $14.65 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mourad Alsabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.